首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives
Authors:Adamo V  Franchina T  Minciullo P L  Pace E  Colonese F  Ricciardi G R R  Saitta S  Ferraro M  Spatari G  Gangemi S
Institution:Department of Human Pathology, Unit of Integrated Therapies in Oncology, University of Messina, Italy.
Abstract:Expression of IL‐23, a heterodimeric cytokine involved in the induction of Th17 cells, is increased in human tumors. Although the endogenous IL‐23 expression has been reported to promote tumor development and growth, the studies using local and systemic administration of IL‐23 have shown that its application at the excessive amount induces antitumor immune responses. IL‐23 is, today, considered the key driver of intestinal inflammation and its role in inflammatory responses is tissue‐specific. The aim of this study was to investigate the role of circulating levels of IL‐23 in patients with resected colorectal cancer (CRC) before and after chemotherapy, respect to healthy controls. Twenty‐five patients were enrolled between June 2007 and January 2009, and followed through 2010. All patients underwent chemotherapy, mostly FOLFOX4. Twenty‐sex and age‐matched healthy donors were recruited as controls. IL‐23 serum concentrations, measured by a quantitative enzyme immunoassay technique, were significantly higher in patients with resected CRC (26.02 ± 28.63 pg/ml versus 7.1 ± 6.4 pg/ml, P < 0.001) and after chemotherapy respect to controls (21.74 ± 23.82 pg/ml versus 7.17 ± 6.43 pg/ml, P < 0.001). An increase was documented also before chemotherapy (26.02 ± 28.63 pg/ml versus 21.74 ± 23.82 pg/ml, P = 0.7) but not statistically significant. This work investigated, for the first time, the role of IL‐23 in CRC resection and chemotherapy, showing no correlation with the severity of disease, tumor removal, and chemotherapeutic treatment. However, other works are needed to better clarify if IL‐23 could be considered a key‐molecule in human CRC and a target for tumor treatment. J. Cell. Physiol. 226: 3032–3034, 2011. © 2011 Wiley‐Liss, Inc.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号